3,4,5-Trihydroxy benzoic acid (gallic acid), the hepatoprotective principle in the fruits of Terminalia belerica-bioassay guided activity.
Compound I isolated from fraction TB5 of Terminalia belerica and finally identified as 3,4,5-trihydroxy benzoic acid (gallic acid) was evaluated for its hepatoprotective activity against carbon tetrachloride (CCl4)-induced physiological and biochemical alterations in the liver. The main parameters studied were hexobarbitone-induced sleep, zoxazolamine induced paralysis, serum levels of transaminases and bilirubin. The hepatic markers assessed were lipid peroxidation, drug metabolising enzymes, glucose-6-phosphatase and triglycerides. Administration of Compound I led to significant reversal of majority of the altered parameters. Our results confirm the presence of hepatoprotective activity in altered parameters. Our results confirm the presence of hepatoprotective activity in Compound I.
Anand
K K
KK
Division of Pharmacology, Regional Research Laboratory, Jammu-Tawi, India.
Singh
B
B
Saxena
A K
AK
Chandan
B K
BK
Gupta
V N
VN
Bhardwaj
V
V
D000818:Animals; D002252:Carbon Tetrachloride Poisoning / Q000188:drug therapy*; D056486:Chemical and Drug Induced Liver Injury; D005260:Female; D005707:Gallic Acid / Q000302:isolation & purification* / Q000627:therapeutic use*; D006591:Hexobarbital / Q000037:antagonists & inhibitors; D015227:Lipid Peroxidation / Q000187:drug effects; D008107:Liver Diseases / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D008515:Medicine, Ayurvedic; D051379:Mice; D008517:Phytotherapy; D010946:Plants, Medicinal / Q000737:chemistry* / Q000627:therapeutic use; D051381:Rats; D012838:Silymarin / Q000627:therapeutic use; D015049:Zoxazolamine / Q000037:antagonists & inhibitors
D012838:Silymarin; D005707:Gallic Acid; D015049:Zoxazolamine; D006591:Hexobarbital